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Abstract
Boldine, a major aporphine alkaloid found in Chilean boldo tree, is a potent antioxidant. Oxidative stress plays a detrimental
role in the pathogenesis of endothelial dysfunction in hypertension. In the present study, we investigated the effects of boldine
on endothelial dysfunction in hypertension using spontaneously hypertensive rats (SHR), the most studied animal model of
hypertension. SHR and their age-matched normotensive Wistar-Kyoto (WKY) rats were treated with boldine (20 mg/kg per
day) or its vehicle, which served as control, for seven days. Control SHR displayed higher systolic blood pressure (SBP),
reduced endothelium-dependent aortic relaxation to acetylcholine (ACh), marginally attenuated endothelium-independent
aortic relaxation to sodium nitroprusside (SNP), increased aortic superoxide and peroxynitrite production, and enhanced
p47phox protein expression as compared with control WKY rats. Boldine treatment significantly lowered SBP in SHR but
not in WKY. Boldine treatment enhanced the maximal relaxation to ACh in SHR, but had no effect in WKY, whereas the
sensitivity to ACh was increased in both SHR and WKY aortas. Boldine treatment enhanced sensitivity, but was without
effect on maximal aortic relaxation responses, to SNP in both WKY and SHR aortas. In addition, boldine treatment lowered
aortic superoxide and peroxynitrite production and downregulated p47phox protein expression in SHR aortas, but had no
effect in the WKY control. These results show that boldine treatment exerts endothelial protective effects in hypertension,
achieved, at least in part, through the inhibition of NADPH-mediated superoxide production.
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Introduction
Hypertension is the most important risk factor for cardio-
vascular disease, which is the leading cause of death and
illness throughout the world.1 Endothelial dysfunction,
which is mostly manifested as impairment in endothelium-
derived nitric oxide (NO)-dependent vasodilation of blood
vessels, represents a major risk factor for hypertension.2,3
Therefore, interventions that can restore endothelial function
are likely to improve clinical outcome in hypertensive sub-
jects. One such intervention that has received much attention
in recent times is supplementation with ‘natural’ antioxi-
dants, confounded by the fact that increased production of
reactive oxygen species (ROS) plays a critical role in the
pathogenesis of endothelial dysfunction in hypertension.4,5
Boldine, an aporphine alkaloid, is a potent ‘natural’ anti-
oxidant found majorly in leaf and bark of the Chilean boldo
(Peumus boldusMolina) tree.6,7 In earlier studies, boldine has
been demonstrated to have anti-inﬂammatory, antipyretic,
antidiabetic, antiatherogenic, antiplatelet, antitumor pro-
moting and cytoprotective effects, which stem from its
potent antioxidant actions.6 For instance, treatment with
boldine decreased artherogenic lesion formation and inhib-
ited oxidation of low density lipoprotein in LDLR2/2
mice.8 Apart from its antioxidant effects, boldine can also
promote vascular smooth muscle relaxation.9 However, to
the best of our knowledge, no studies at this point in time
have demonstrated the effects of boldine in hypertension.
This study, therefore, evaluated the effectiveness of
boldine in the treatment of endothelial dysfunction in spon-
taneously hypertensive rats (SHR), the most studied exper-
imental model of hypertension. Our own interest in
boldine arose from the observation that (1) it is widely
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found in the bark of local tree Phoebe grandis and (2) boldine-
containing herbal teas are widely consumed around the
world, in particular in South America.6,10
Materials and methods
Animals and experimental protocol
Male spontaneously hypertensive (SHRs) and Wistar-Kyoto
(WKYs) rats (17–18 weeks old) were obtained from the
University of Malaya Animal Unit, and all the experimental
procedures were approved by the University of Malaya
Animal Care and Ethics Committee. The animals were
housed in a well ventilated room (temperature: 24+18C),
and had free access to standard rat chow and tap water.
The rats were randomized to receive boldine vehicle (20%
Tween 80), which served as control, or boldine (20 mg/kg).
The treatments were given by intraperitoneal injection, once
daily for seven days. To avoid the possible involvement of
acute effects of the treatment, all the post-treatment exper-
iments were conducted at least 24 h after the ﬁnal treatment.
Non-invasive measurement of blood pressure
Systolic blood pressure (SBP) was measured prior to and
after the treatment period by tail-cuff plethysmography
(NIBP machine, IITC Inc, Woodland Hills, CA, USA).
Blood pressure values for individual rats were obtained
from the average of eight consecutive measurements and
were monitored in the morning at the same period of the
time of the day.
Measurement of ex vivo vascular function
After measurement of blood pressure, the rats were anesthe-
tized with a single intraperitoneal dose of pentobarbitone
sodium (60 mg/kg body weight) and sacriﬁced by cervical
dislocation. Thereafter, the descending thoracic aorta was
rapidly removed and cleaned of fat and connective tissues.
The aortas were sectioned into small rings (3–5 mm in
width) and placed in jacketed organ baths (one ring in
each bath) containing 5 mL of Krebs physiological salt sol-
ution composed of (mmol/L): NaCl 118.2, NaHCO3 25.0,
KCl 4.7, KH2PO4 1.2, MgSO4.7H2O 1.2, glucose 11.7,
CaCl2.2H2O 2.5 and ethylenediaminetetraacetic acid 0.026.
The bath solution was maintained at 378C and aerated con-
tinuously with a mixture of 95% O2 and 5% CO2. The rings
were connected to isometric force–displacement transdu-
cers (Grass Instrument Co, Quincy, MA, USA) and the
output was ampliﬁed and recorded continuously using
the Mac Lab recording system (AD Instruments, Sydney,
Australia). The rings were equilibrated for 45 min under
1.0 g resting tension. After the equilibration period, the con-
tractile responses of aortic rings were tested for viability by
the repeated addition of high KCl solution (high Kþ,
80 mmol/L). Once reproducible contractions were obtained
with high Kþ, the aortic rings were contracted with seroto-
nin (30 mmol/L) and the concentration–response curves to
endothelium-dependent and -independent vasodilators,
acetylcholine (ACh, 10210 to 1025 mol/L) and sodium
nitroprusside (SNP, 10211 to 1026 mol/L), respectively,
were recorded. ACh or SNP was added cumulatively at
three-minute intervals between successive doses. The
choice of serotonin over more conventionally used phenyl-
ephrine to test the relaxation responses to ACh and SNP
was prompted by earlier investigations which demonstrated
that boldine may interact with a1-adrenoceptors and Ca2þ
channels.11,12
Measurement of superoxide anion production
Levels of superoxide production from aortas isolated from
different groups of rats were measured using the
lucigenin-enhanced chemiluminescence (LEC) method
with a luminometer (CHAMELEONTM V; Hidex, Turku,
Finland).13,14 After clearing of fat and connective tissues,
aortic rings were rinsed in Krebs-HEPES buffer (compo-
sition in mmol/L: NaCl 99.0, NaHCO3 25, KCl 4.7,
KH2PO4 1.0, MgSO4.7H2O 1.2, glucose 11.0, CaCl2.2H2O
2.5 and Na-HEPES 20.0) and incubated for 45 min at 378C
in the presence and absence of diphenylene iodonium
(DPI, 5 mmol/L), an NADPH oxidase inhibitor, in
Krebs-HEPES buffer containing 1 mmol/L diethylthiocarba-
mic acid (DETCA) and 0.1 mmol/L b-nicotinamide adenine
dinucleotide phosphate (NADPH). After the incubation
period, the rings were washed with Krebs-HEPES buffer
and transferred to a 96-well plate with one ring in each
well containing 300 mL Krebs-HEPES buffer with lucigenin
(5 mmol/L) and NADPH (0.1 mmol/L). The plate was
immediately loaded into a luminometer and the output of
LEC was recorded. Thereafter, the rings were dried for
48 h at 658C and weighed. The levels of superoxide gener-
ation were normalized to milligrams dry weight of tissue.
Measurement of peroxynitrite production
Levels of peroxynitrite production from aortas isolated from
different groups of rats were measured using the
luminol-enhanced chemiluminescence method with a
luminometer (CHAMELEONTM V, Hidex).15 This method
is similar to that used for superoxide detection with the
exceptions that (1) luminol (100 mmol/L) is used instead of
lucigenin and (2) aortic rings were incubated in
Krebs-HEPES buffer containing 1 mmol/L DETCA and
0.1 mmol/L NADPH in the presence and absence of uric
acid (250 mmol/L), a scavenger of peroxynitrite.
Measurement of p47phox protein expression
Aortas isolated from different groups of rats were frozen
in liquid nitrogen and stored at 2808C until analyzed.
Aortas were homogenized in ice-cold 1 RIPA buffer
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) by using
gentleMACSTM dissociator (Miltenyi Biotec Inc, Bergisch
Gladbach, Germany). The lysates were then centrifuged and
supernatants were collected for Western blotting. Protein con-
centrations of the supernatant were determined by Bradford
assay. For each sample, 30 mg of total tissue protein was sep-
arated in 10% sodium dodecyl sulphate polyacrylamide gel
and transferred onto nitrocellulose membranes at 100 V for
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90 min. The blots were blocked for non-speciﬁc binding with
3% bovine serum albumin (BSA) in Tris-buffered saline con-
taining 0.1% Tween-20 (TBS-T) for one hour at room tempera-
ture with gentle shaking. It was then washed three times with
TBS-T and incubated overnight at 48C with primary mouse
monoclonal antibody (1:500 dilution; Santa Cruz
Biotechnology). The membranes were washed three times
for ﬁve minutes in TBS-T and incubated with secondary
goat anti-mouse antibody conjugated to horseradish peroxi-
dise for one hour at room temperature. After extensive
washing of the membrane, the bands were detected using
3,30,5,50-tetramethylbenzidine liquid substrate system
(Sigma, St Louis, MO, USA). The membrane image was cap-
tured under the Gel DOC XR system (Bio-Rad Laboratories,
Hercules, CA, USA) and densitometric analysis was per-
formed using Quantity Onew 1-D analysis software. The
p47phox protein expression levels were normalized to a-actin
and data are expressed as a percentage of the values in the
WKY control group.
Drugs and chemicals
ACh chloride, serotonin hydrochloride, bis-N-methylacridi-
nium nitrate (lucigenin), DETCA, DPI, b-NADPH, 5-amino-
2,3-dihydro-1,4-phthalazinedione (luminol), boldine, uric acid
and Tris-base were purchased from Sigma Chemicals
Company (St Louis, MO, USA). BSA and Tween-20 were pur-
chased from Bio-Rad Laboratories. SNP and Kreb’s salts were
purchased from BDH Limited and BDH Laboratory Supplies
(Poole, UK), respectively.
Statistical analysis
All results are presented as mean+ standard error of mean
(SEM) for number (n) of rats in each experimental group.
Concentration–response curves were ﬁtted to a sigmoidal
curve using non-linear regression with the aid of the statisti-
cal software GraphPad Prism Version 4 (GraphPad
Software, La Jolla, CA, USA). Agonist sensitivity (pEC50)
and maximal response (Rmax) for each group were obtained
from the curves. The observed responses were analyzed for
statistical signiﬁcance using Student’s t-test for unpaired
observations and the one-way analysis of variance
(ANOVA) followed by Bonferroni’s multiple comparison
test for multiple value comparison (Prism 2.0, GraphPad
Software). A value of P, 0.05 was considered statistically
signiﬁcant.
Results
Effect of boldine treatment on blood pressure
Table 1 summarizes the mean+SEM values for SBP in
different groups of animals. SBP was elevated in SHR
animals compared with WKY animals (Table 1). Boldine
treatment (20 mg/kg per day, intraperitoneally) had no sig-
niﬁcant effect on SBP of WKY rats, but signiﬁcantly lowered
it in SHR animals (Table 1).
Effect of boldine treatment on vascular function
Figure 1 depicts the relaxation responses to ACh (panel A)
and SNP (panel B) in aortic rings isolated from vehicle
(control)- or boldine-treated WKY and SHR animals.
Aortic rings from control SHR in general showed lesser
relaxation responses to ACh and SNP compared with
respective responses in control WKY aortic rings (Figure 1
and Table 2). Aortic rings from boldine-treated WKY and
SHR animals demonstrated enhanced sensitivity to ACh
and SNP compared with equivalent responses in respective
control rats (Table 2). The maximal relaxation response to
ACh was markedly increased in aortic rings obtained from
boldine-treated SHR compared with control SHR aortic
rings, but remain essentially similar in the control and
boldine-treated WKY rings (Table 2). The maximal relax-
ation response to SNP remains unaltered in aortic rings
from boldine-treated WKY and SHR animals compared
with equivalent responses observed in respective control
rats (Table 2).
Effects of boldine treatment on superoxide anion
production
Levels of superoxide anion generation in aortic rings from
vehicle or boldine-treated WKY and SHR rats are shown
in Figure 2. Superoxide levels were increased in control
SHR aortas compared with control WKY aortas, and this
increase was totally abolished in the presence of DPI, a
NADPH oxidase inhibitor (Figure 2). There were no signiﬁ-
cant differences in superoxide generation between control
Figure 1 Endothelium-dependent and -independent relaxations to acetyl-
choline (ACh, a) and sodium nitroprusside (SNP, b), respectively, in aortic
rings isolated from control and boldine-treated Wistar-Kyoto rats (WKY) and
spontaneously hypertensive rats (SHR). Data are expressed as mean+SEM
(n ¼ 6–7). 5-HT, 5-hydroxytryptamine. P, 0.001 compared with respective
control group
Table 1 Pre- and post-treatment systolic blood pressure among
control (vehicle-treated) and boldine-treated Wistar-Kyoto rats (WKY)
and spontaneously hypertensive rats (SHR)
Systolic blood pressure (mmHg)
Experimental group Before After
WKY-control 104.6+2.37 110.8+1.87
WKY-boldine 107.1+3.40 111.6+2.91
SHR-control 190.2+2.92 192.4+1.97
SHR-boldine 193.5+1.23 166.9+1.44†
Data are expressed as mean+SEM (n ¼ 6–7)
P, 0.001 compared with WKY-control
†P, 0.001 compared with SHR-control
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and boldine-treated WKY rat aortas. Aortas from SHR
treated with boldine demonstrated signiﬁcant reduction in
superoxide generation compared with control SHR aortas.
There were no signiﬁcant differences observed in superox-
ide generation from control and boldine-treated WKY and
SHR aortas in the presence of DPI (Figure 2).
Effects of boldine treatment on peroxynitrite
production
Levels of peroxynitrite generation in aortic rings from
vehicle- or boldine-treated WKY and SHR rats are shown
in Figure 3. Peroxynitrite levels were increased in control
SHR aortas compared with control WKY aortas, and this
difference was completely abolished in the presence of per-
oxynitrite scavenger, uric acid (Figure 3). There were no sig-
niﬁcant differences in peroxynitrite generation between
control and boldine-treated WKY rat aortas. Aortas from
SHR treated with boldine demonstrated signiﬁcant
reduction in peroxynitrite generation compared with
control SHR aortas. There was no signiﬁcant difference
observed in peroxynitrite generation from control and
boldine-treated WKY and SHR aortas in the presence of
uric acid (Figure 3).
Effects of boldine treatment on p47phox protein
expression
The p47phox protein expression was signiﬁcantly higher in
control SHR aortas as compared with control WKY aortas
(Figure 4). Boldine treatment signiﬁcantly reduced p47phox
protein expression in SHR but had no effect in WKY
(Figure 4).
Discussion
The present study investigated, for the ﬁrst time, the effects
of boldine treatment (20 mg/kg per day) on endothelial dys-
function in hypertension. The novel ﬁndings of the present
study are that boldine treatment improved impaired
endothelial-dependent vasorelaxation in SHR aortas. In
addition, boldine treatment also decreased superoxide and
peroxynitrite concentrations and p47phox protein expression
in SHR aortas. Furthermore, boldine treatment decreased
SBP in SHR. Collectively, these ﬁndings suggest an appar-
ent protective role for boldine in the treatment of endothelial
dysfunction in hypertension.
The present results demonstrated that boldine treatment
signiﬁcantly reduced mean SBP in SHR (Table 1). While
the possibility of a direct vasodilator effect of boldine
could be entertained in this phenomenon, this appears unli-
kely as blood pressure measurements were recorded at least
24 h after the ﬁnal treatment with boldine. Scavenging of
endothelium-derived NO by increased superoxide anion,
leading to inadequate NO concentrations and to increased
formation of peroxynitrite, can contribute to the diminished
role of NO in the regulation of blood pressure in hyperten-
sion.16 Indeed, despite some paradoxical ﬁndings, several
studies have shown that treatment with antioxidants such
as ascorbic acid reduced blood pressure in humans and in
Table 2 Agonist sensitivity (pEC50) and % maximum response (Rmax) of endothelium-dependent and -independent vasodilators acetylcholine
(ACh) and sodium nitroprusside (SNP), respectively, in aortic rings isolated from control and boldine-treated Wistar-Kyoto rats (WKY) and spon-
taneously hypertensive rats (SHR)
Ach SNP
Group pEC50 (mol/L) Rmax (%) pEC50 (mol/L) Rmax (%)
WKY-control 6.52+0.48 88.44+1.85 8.01+0.23 100.50+4.90
WKY-boldine 7.68+0.21‡ 90.38+3.05 8.37+0.07‡ 109.67+2.74
SHR-control 7.96+0.12 40.60+5.64 7.61+0.55 102.00+1.97
SHR-boldine 8.28+0.13† 94.67+5.28† 8.47+0.20† 106.80+4.00
Data are expressed as mean+SEM (n ¼ 6–7)
P, 0.001 compared with WKY-Control
†P, 0.00l compared with SHR-Control
‡P, 0.05 compared with WKY-Control
Figure 3 Levels of peroxynitrite generation in aortic rings from control and
boldine-treated Wistar-Kyoto rats (WKY) and spontaneously hypertensive
rats (SHR). Results are mean+SEM (n ¼ 4–6). P, 0.01 compared with
WKY-Control. P, 0.01 compared with SHR-Control
Figure 2 Levels of superoxide anion generation in aortic rings from control
and boldine-treated Wistar-Kyoto rats (WKY) and spontaneously hypertensive
rats (SHR). Results are shown as mean+SEM (n ¼ 8–10). P, 0.001 com-
pared with WKY-Control. P, 0.01 compared with SHR-Control
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animal models of hypertension including SHR.17–21 In the
present study, boldine treatment reduced superoxide
anion/peroxynitrite production in SHR, suggesting that by
inhibiting/decreasing superoxide anion, boldine reduced
blood pressure in SHR. A superoxide decreasing role for
boldine in reduced blood pressure in SHR also gains
ground from the ﬁnding that boldine treatment failed to
alter blood pressure in normal WKY rats in which the vas-
cular superoxide anion production is expected to be too
little (or even negligible) to affect the regulatory functions
of endothelium-derived NO.
Impaired endothelium-dependent relaxations have been
observed in different animal models of hypertension includ-
ing SHR.5,22–24 Consistent with these reports, the results of
the present study demonstrated that endothelium-
dependent relaxation responses to ACh were signiﬁcantly
lesser in SHR aortas compared with their WKY counterparts
(Figure 1a). Present results also demonstrate that treatment
with boldine signiﬁcantly improved endothelium-
dependent relaxation responses to ACh in SHR aortas
(Figure 1a), indicating improvement in endothelial function
in these hypertensive animals. One important mechanism
for impaired endothelium-dependent relaxations in SHR is
increased production of superoxide anion.4,5 Superoxide
anion reacts with endothelium-derived NO to form peroxy-
nitrite, leading to impaired endothelium-dependent relax-
ations in hypertension.4,5 Boldine is a potent antioxidant,
as evidenced by inhibition of superoxide anion and other
ROS in earlier studies.6,25,26 For example, in an earlier
study, we have shown that boldine inhibited peroxyl
radical formation in a cell-free xanthine/xanthine oxidase
superoxide generation system.27 In the present study,
boldine treatment signiﬁcantly attenuated superoxide and
peroxynitrite production in SHR aortas (Figure 2). In
addition, boldine treatment also decreased p47phox protein
expression in SHR aortas. It is well known that p47phox
regulates the activity of NADPH-dependent oxidases,
which play a major role in increased superoxide anion
production in hypertensive vasculature. NADPH oxidase
is a multicomponent enzyme that comprises a membrane-
bound cytochrome b558 (p22phox and gp91phox) and
regulatory cytosolic proteins (p47phox and p67phox),
which has been found in membranes of all vascular cells
including endothelial cells, vascular smooth muscle cells
and ﬁbroblasts.28,29 By inhibiting NADPH-mediated pro-
duction of superoxide anion in both endothelial cells and
smooth muscle cells, NO bioavailabilty can be improved,
which helps in vasorelaxation. Put together, these obser-
vations suggest that boldine treatment improves endothelial
function in SHR, at least in part, through inhibition of
NADPH-mediated superoxide anion production and sub-
sequently improving endothelial NO bioavailability. In
support of this, boldine treatment enhanced total plasma
nitrite/nitrate (NOx) levels in SHR but not in WKY rats
(data not shown).
Interestingly, in the present study, we found that aortic
rings from boldine-treated WKY rats demonstrated higher
sensitivity to ACh-induced relaxation compared with
control WKY aortas. This improvement in WKY aortas, as
argued above, cannot be attributed to antioxidant activity
of boldine. This is because boldine treatment had no effect
on superoxide and peroxynitrite production in WKY aortas
(Figures 2 and 3). In addition, normotensive WKY tissues
produce little or no free radicals.30,31 In earlier studies,
boldine had been reported to elicit smooth muscle-relaxing
effects,11 which may well contribute to improved relaxation
to ACh observed in the present study. However, with the vas-
cular reactivity studies performed at least 24 h after the ﬁnal-
day treatment, this possibility is unlikely. On the other hand,
however, boldine treatment improved the sensitivity of WKY
aortic rings to the endothelium-independent vasodilator, SNP
(Figure 1b), thus supporting the view that boldine improved
the sensitivity of WKY aortas to ACh. Both ACh and SNP
cause smooth muscle relaxation by the same effector mechan-
ism, with the exception that ACh-induced relaxation requires
release of NO from the endothelium whereas SNP breaks
down spontaneously to release NO independently of the
endothelium.32,33 Once released, NO diffuses into adjacent
smooth muscle cells and leads to soluble guanylate cyclase
(sGC) activation, cyclic guanosine monophosphate (cGMP)
elevation and ultimately to vascular smooth muscle relax-
ation.32,33 Putting these observations together, it appears
that the effects of boldine not only reside upstream of the
NO-sGC-cGMP cascade (i.e. preservation of NO bioavailabil-
ity), but also reside downstream of the NO-sGC-cGMP
cascade (i.e. enhancement in cGMP accumulation and NO
bioactivity). The direct measurement of cGMP production,
which we were unable to perform in this study, will be
useful in further clarifying these assumptions.
Lastly, in the present study, despite normalizing oxidative
stress parameters, boldine treatment failed to completely
normalize the elevated blood pressure in SHR. The exact
mechanism(s) of this discrepancy is unclear; however, it
is noteworthy to mention that several oxidative stress-
independent factors, for example, alterations in sympathetic
nervous system, can also contribute to the development of
hypertension in SHR. On the other hand, it is also important
to note that, whereas all the above observations suggest the
Figure 4 Protein expression levels of p47phox in aortic rings from control and
boldine-treated Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats
(SHR). Results are mean+SEM (n ¼ 4) of densitometric values normalized to
corresponding a-actin and expressed as a percentage of WKY-control.
P, 0.05 compared with WKY-Control
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possibility that by decreasing superoxide anion, boldine
reduced blood pressure and improved endothelium-
dependent relaxations in SHR, present ﬁndings neither
support nor rule out a role for other actions of boldine, for
example, anti-inﬂammatory actions in its observed effects.
In summary, the present results show that boldine treat-
ment improves endothelial function in SHR, in part, by inhi-
biting NADPH-mediated superoxide production. The
present results point to a potential therapeutic use for
boldine in the management of elevated blood pressure
and endothelial dysfunction in hypertension.
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